What is the 13F Pro Quality Score for ENTA?

13F Pro ranks ENANTA PHARMACEUTICALS INC (ENTA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ENTA's current score at https://13fpro.ai/company/ENTA (free sign-up required for the full ranking).

Which hedge funds own the most ENTA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ENTA include Jupiter Topco, BlackRock,, Krensavage Asset Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ENTA as soon as new 13F filings post.

Where does 13F Pro source ENTA data?

All ENANTA PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. ENANTA PHARMACEUTICALS INC files with the SEC under CIK 1177648. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ENTA in?

ENANTA PHARMACEUTICALS INC (ENTA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ENTA research updated on 13F Pro?

ENTA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ENANTA PHARMACEUTICALS INC(ENTA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1177648 ENTA stock profile & AI dashboard →

13F Pro Quality Score

17.8/100

Rank #2,821 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

13.4/100

Profitability

7.6/100

Balance Sheet

10.6/100

Earnings Quality

32.3/100

Free Cash Flow

8.7/100

Institutional Flow

41.8/100

Revenue Scale

11.2/100

Dilution Risk

6.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ENTA Scores 18/100

exact factor attribution · 2026-09-11

ENTA's composite is driven by earnings growth, held back by revenue growth and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+1.8 pts

86th pct

Institutional flow

-0.4 pts

42th pct

Earnings quality

-1.8 pts

32th pct

Shareholder dilution

-2.2 pts

7th pct

Capital efficiency

-3.9 pts

11th pct

Scale

-5.8 pts

11th pct

Free cash flow

-6.2 pts

9th pct

Profitability

-6.4 pts

8th pct

Revenue growth

-7.3 pts

13th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ENTA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for ENANTA PHARMACEUTICALS INC (ENTA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ENTA at 17.8/100 on a 32-signal composite quality model, placing it at rank #2,821 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (7.6) and free cash flow (8.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ENANTA PHARMACEUTICALS INC reports quarterly revenue of $14.4M, net income of $-19.5M, free cash flow of $-10.0M. Top institutional holders of ENTA by reported 13-F value include Jupiter Topco, BlackRock, Krensavage Asset Management, based on the most recent SEC filings. ENTA trades on the Nasdaq exchange and files with the SEC under CIK 1177648. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ENANTA PHARMACEUTICALS INC directly from SEC EDGAR. ENANTA PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 10 and 22 since 2021, currently 17.8 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about ENANTA PHARMACEUTICALS INC

Quirks, history, and lore behind ENTA — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. biopharmaceutical company · listed on Nasdaq · headquartered in Massachusetts · focused on infectious disease.
2
The Numbers
With a market cap in the low hundreds of millions and no commercial product revenue of its own, it survives largely on collaboration income from a larger pharma partner.
3
The History
Founded in the early 2000s, the company built its pipeline around macrocyclic chemistry — a specialized drug-design approach that helps target slippery viral proteins.
4
The Secret
Its biggest commercial win wasn't even sold under its own name — a key compound it developed ended up inside AbbVie's blockbuster hepatitis C regimen, generating royalty-style payments.
5
The Lore
After the hepatitis C market cratered faster than anyone expected, the company pivoted hard toward RSV and COVID antivirals, betting its future on the next respiratory menace.
6
The Giveaway
This Watertown, MA biotech supplied chemistry brainpower behind Mavyret and now chases its own antiviral glory under the ticker ENTA.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$14.4M

Net Income

Q2 2026

$-19.5M

Free Cash Flow

Q2 2026

$-10.0M

ROIC

Q2 2026

-68.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-3.4% YoY

$65.3MFY 2025

FY22 $86.2MFY23 $79.2MFY24 $67.6MFY25 $65.3M

Net Income

+29.4% YoY

$-81.9MFY 2025

FY22 $-121.8MFY23 $-133.8MFY24 $-116.0MFY25 $-81.9M

Operating Income

+29.9% YoY

$-85.3MFY 2025

FY22 $-123.8MFY23 $-137.2MFY24 $-121.7MFY25 $-85.3M

EPS (Diluted)

+29.9% YoY

$-3.84FY 2025

FY22 $-5.91FY23 $-6.38FY24 $-5.48FY25 $-3.84

Total Assets

-25.5% YoY

$280.7MFY 2025

FY22 $375.4MFY23 $462.3MFY24 $376.7MFY25 $280.7M

Op. Cash Flow

+75.5% YoY

$-19.3MFY 2025

FY22 $-84.8MFY23 $-103.2MFY24 $-78.8MFY25 $-19.3M

Free Cash Flow

+66.7% YoY

$-32.2MFY 2025

FY22 $-86.9MFY23 $-112.2MFY24 $-96.7MFY25 $-32.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$65.3M -3.4%	$67.6M -14.6%	$79.2M -8.1%	$86.2M -11.2%	$97.1M -20.7%	$122.5M
Net Income	$-81.9M +29.4%	$-116.0M +13.3%	$-133.8M -9.9%	$-121.8M -54.1%	$-79.0M -118.4%	$-36.2M
Operating Income	$-85.3M +29.9%	$-121.7M +11.3%	$-137.2M -10.8%	$-123.8M -13.0%	$-109.6M -163.1%	$-41.6M
EPS (Diluted)	$-3.84 +29.9%	$-5.48 +14.1%	$-6.38 -8.0%	$-5.91 -50.8%	$-3.92 -116.6%	$-1.81
Total Assets	$280.7M -25.5%	$376.7M -18.5%	$462.3M +23.1%	$375.4M -14.4%	$438.8M -9.7%	$486.1M
Operating Cash Flow	$-19.3M +75.5%	$-78.8M +23.6%	$-103.2M -21.7%	$-84.8M -21.1%	$-70.0M -1087.5%	$7.1M
Free Cash Flow	$-32.2M +66.7%	$-96.7M +13.8%	$-112.2M -29.1%	$-86.9M -22.8%	$-70.7M -1353.7%	$5.6M

Get alerted when ENTA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ENANTA PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ENTA

Jupiter Topco LLC
$53.3M3,654,920 sh
BlackRock, Inc.
$47.3M3,244,448 sh
Krensavage Asset Management, LLC
$41.8M2,866,138 sh
FARALLON CAPITAL MANAGEMENT LLC
$35.3M2,418,202 sh
Deep Track Capital, LP
$21.1M1,444,167 sh
ADAR1 Capital Management, LLC
$19.6M1,344,510 sh
VANGUARD CAPITAL MANAGEMENT LLC
$17.7M1,211,769 sh
Spruce Street Capital LP
$15.9M1,088,731 sh
ACADIAN ASSET MANAGEMENT LLC
$15.7M1,078,317 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$14.7M1,011,494 sh

Fund	Value	Shares
Jupiter Topco LLC	$53.3M	3,654,920
BlackRock, Inc.	$47.3M	3,244,448
Krensavage Asset Management, LLC	$41.8M	2,866,138
FARALLON CAPITAL MANAGEMENT LLC	$35.3M	2,418,202
Deep Track Capital, LP	$21.1M	1,444,167
ADAR1 Capital Management, LLC	$19.6M	1,344,510
VANGUARD CAPITAL MANAGEMENT LLC	$17.7M	1,211,769
Spruce Street Capital LP	$15.9M	1,088,731
ACADIAN ASSET MANAGEMENT LLC	$15.7M	1,078,317
VANGUARD PORTFOLIO MANAGEMENT LLC	$14.7M	1,011,494

Companies Similar to ENTA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

XNCR

Xencor Inc

AI score

Very similar · 5 shared holders

Deep Track Capital, LP ADAR1 Capital Management, LLC Susquehanna Portfolio Strategies, LLC

KROS

Keros Therapeutics, Inc.

AI score

Very similar · 6 shared holders

ADAR1 Capital Management, LLC MARTINGALE ASSET MANAGEMENT L P Susquehanna Portfolio Strategies, LLC

VYGR

Voyager Therapeutics, Inc.

AI score

Similar quality profile · 5 shared holders

Opaleye Management Inc.Susquehanna Portfolio Strategies, LLC ADAR1 Capital Management, LLC

VNDA

Vanda Pharmaceuticals Inc.

AI score

Similar quality profile · 5 shared holders

Krensavage Asset Management, LLC MARTINGALE ASSET MANAGEMENT L P Susquehanna Portfolio Strategies, LLC

PSNL

Personalis, Inc.

AI score

Similar quality profile · 6 shared holders

Deep Track Capital, LP Susquehanna Portfolio Strategies, LLC ADAR1 Capital Management, LLC

ALEC

Alector, Inc.

AI score

Similar quality profile · 3 shared holders

ADAR1 Capital Management, LLC Spruce Street Capital LP China Universal Asset Management Co., Ltd.

NRIX

Nurix Therapeutics, Inc.

AI score

Similar quality profile · 7 shared holders

Deep Track Capital, LP ADAR1 Capital Management, LLC SummitTX Capital, L.P.

ALMS

ALUMIS INC.

AI score

Similar quality profile · 6 shared holders

Deep Track Capital, LP Spruce Street Capital LP Opaleye Management Inc.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ENTA on your watchlist

Track score changes the day ENANTA PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ENTA a good stock to buy?

13F Pro's AI-powered analysis of ENANTA PHARMACEUTICALS INC (ENTA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ENTA are available on the ENTA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ENTA is classified as a small company.

Which hedge funds own ENTA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ENTA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ENANTA PHARMACEUTICALS INC's investment landscape.